Market Overview

Novartis Division Alcon Receives FDA Approval for AcrySof®IQ Aspheric IOL with UltraSert Pre-loaded Delivery System

Share:
Related NVS
Mark Your Calendar For These Days In May To Play The Volatility Around FDA Decision Dates
Earnings Scheduled For April 25, 2017
Psst! Mutual Fund Managers Dish About Stocks They Like (Investor's Business Daily)

Alcon, the global leader in eye care and a division of Novartis (NYSE: NVS), has received US Food and Drug Administration (FDA) approval for its AcrySof® IQ Aspheric IOL with the UltraSertTM Pre-loaded Delivery System for patients undergoing cataract surgery. This new delivery system combines the control of a manually loaded device…Alcon, the global leader in eye care and a division of Novartis, has received US Food and Drug Administration (FDA) approval for its AcrySof® IQ Aspheric IOL with the UltraSertTM Pre-loaded Delivery System for patients undergoing cataract surgery. This new delivery system combines the control of a manually loaded device with the safety and convenience of a disposable, pre-loaded injector to optimize the implantation of the AcrySof IQ Aspheric IOL into the cataract patient's eye. Nearly four million cataract surgeries are performed each year in the US[1]. The UltraSertTM Pre-loaded Delivery System received the European CE mark in June 2015.

See full press release

Posted-In: News FDA Press Releases

 

Related Articles (NVS)

View Comments and Join the Discussion!